medigraphic.com
ISSN 0016-3813 (Print)

2016, Number 3

<< Back Next >>

Gac Med Mex 2016; 152 (3)

Bone morphogenetic proteins (BMP): clinical application for reconstruction of bone defects

Sierra-García GD, Castro-Ríos R, Gónzalez-Horta A, Lara-Arias J, Chávez-Montes A

Language: Spanish
References: 32
Page: 381-385
PDF size: 91.18 Kb.


ABSTRACT

Since the introduction of bone morphogenetic proteins, their use has become an invaluable ally for the treatment of bone defects. These proteins are potent growth factors, related to angiogenic and osteogenic activity. The osteoinductive capacity of recombinant bone morphogenetic protein (rhBMP) in the formation of bone and cartilage has been confirmed in in vitro studies and evaluated in clinical trials. To obtain a therapeutic effect, administration is systemic, by injection over the physiological dose. Among the disadvantages, ectopic bone formation or high morbidity in cases of spinal fusion is observed. In this review, the roles of bone morphogenetic proteins in bone repair and clinical applications are analyzed. These findings represent advances in the study of bone regeneration and application of growth factors for more predictable results.


REFERENCES

  1. Yilgor P, Sousa RA, Reis RL, Hasirci N, Hasirci V. Effect of scaffold architecture and BMP-2/BMP-7 delivery on in vitro bone regeneration. J Mater Sci Mater Med. 2010;21:2999-3008.

  2. van Baardewijk LJ, van der Ende J, Lissenberg-Thunnissen S, et al. Circulating bone morphogenetic protein levels and delayed fracture healing. Int Orthop. 2013;37:523-7.

  3. Ronga M, Fagetti A, Canton G, Paiusco E, Surace MF, Cherubino P. Clinical applications of growth factors in bone injuries: experience with BMPs. Injury. 2013;44 Suppl 1:S34-9.

  4. Xiong L, Zeng J, Yao A, et al. BMP2-loaded hollow hydroxyapatite microspheres exhibit enhanced osteoinduction and osteogenicity in large bone defects. Int J Nanomedicine. 2015;10:517-26.

  5. Friedlaender GE, Perry CR, Cole JD, et al. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am. 2001;83-A Suppl 1(Pt 2):S151-8.

  6. Zárate-Kalfópulos B, Reyes-Sánchez A. Bone grafts in orthopedic surgery. Cir Cir. 2006;74:217-22.

  7. Bodde EW, Boerman OC, Russel FG, Mikos AG, Spauwen PH, Jansen JA. The kinetic and biological activity of different loaded rhBMP-2 calcium phosphate cement implants in rats. J Biomed Mater Res A. 2008;87: 780-91.

  8. Oryan A, Alidadi S, Moshiri A, Bigham-Sadegh A. Bone morphogenetic proteins: a powerful osteoinductive compound with non-negligible side effects and limitations. Biofactors. 2014;40:459-81.

  9. Mantripragada VP, Jayasuriya AC. Injectable chitosan microparticles incorporating bone morphogenetic protein-7 for bone tissue regeneration. J Biomed Mater Res A. 2014;102:4276-89.

  10. Urist MR. Bone: formation by autoinduction. Science. 1965;150:893-9.

  11. Bragdon B, Moseychuk O, Saldanha S, King D, Julian J, Nohe A. Bone morphogenetic proteins: a critical review. Cell Signal. 2011;23:609-20.

  12. Carreira AC, Lojudice FH, Halcsik E, Navarro RD, Sogayar MC, Granjeiro JM. Bone morphogenetic proteins: facts, challenges, and future perspectives. J Dent Res. 2014;93:335-45.

  13. Tsuji K, Bandyopadhyay A, Harfe BD, et al. BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. Nat Genet. 2006;38:1424-9.

  14. Liu NM, Tian J, Wang WW, et al. Effect of erythropoietin on mesenchymal stem cell differentiation and secretion in vitro in an acute kidney injury microenvironment. Genet Mol Res. 2013;1:6477-87.

  15. Dhar SA, Gani NU, Butt MF, Farooq M, Mir MR. Delayed union of an operated fracture of the femoral neck. J Orthop Traumatol. 2008;9:97-9.

  16. Khanna-Jain R, Agata H, Vuorinen A, Sándor GK, Suuronen R, Miettinen S. Addition of BMP-2 or BMP-6 to dexamethasone, ascorbic acid, and β-glycerophosphate may not enhance osteogenic differentiation of human periodontal ligament cells. Growth Factors. 2010;28:437-46.

  17. Suliman S, Xing Z, Wu X, et al. Release and bioactivity of bone morphogenetic protein-2 are affected by scaffold binding techniques in vitro and in vivo. J Control Release. 2015;197:148-57.

  18. Faßbender M, Minkwitz S, Strobel C, Schmidmaier G, Wildemann B. Stimulation of bone healing by sustained bone morphogenetic protein 2 (BMP-2) delivery. Int J Mol Sci. 2014;15:8539-52.

  19. Vukicevic S, Simic P, Grgurevic L, Boroveck F, Sampath K. Systemic administration of bone morphogenetic proteins. In: Vukicevic S, Sampath K, editores. Bone morphogenetic proteins: from local to systemic therapeutics. Berlin: Birkhauser Verlag AG; 2008. p. 317.

  20. Baltzer AW, Ostapczuk MS, Stosch D, Granrath M. The use of recombinant human bone morphogenetic protein-2 for the treatment of a delayed union following femoral neck open-wedge osteotomy. Orthop Rev (Pavia). 2012;4:e4.

  21. Zimmermann G, Wagner C, Schmeckenbecher K, Wentzensen A, Moghaddam A. Treatment of tibial shaft non-unions: bone morphogenetic proteins versus autologous bone graft. Injury. 2009;40 Suppl 3:S50-3.

  22. Katanec D, Granić M, Majstorović M, Trampus Z, Pandurić DG. Use of recombinant human bone morphogenetic protein (rhBMP2) in bilateral alveolar ridge augmentation: case report. Coll Antropol. 2014;38:325-30.

  23. Kim YJ, Lee JY, Kim JE, Park JC, Shin SW, Cho KS. Ridge preservation using demineralized bone matrix gel with recombinant human bone morphogenetic protein-2 after tooth extraction: a randomized controlled clinical trial. J Oral Maxillofac Surg. 2014;72:1281-90.

  24. Ye L, Bokobza SM, Jiang WG. Bone morphogenetic proteins in development and progression of breast cancer and therapeutic potential (review). Int J Mol Med. 2009;24:591-7.

  25. Kallioniemi A. Bone morphogenetic protein 4 -a fascinating regulator of cancer cell behavior. Cancer Genet. 2012;205:267-77.

  26. Buijs JT, Rentsch CA, van der Horst G, et al. BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. Am J Pathol. 2007;171:1047-57.

  27. Klose A, Waerzeggers Y, Monfared P, et al. Imaging bone morphogenetic protein 7 induced cell cycle arrest in experimental gliomas. Neoplasia. 2011;13:276-85.

  28. Fu R, Selph S, McDonagh M, et al. Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine fusion: a systematic review and meta-analysis. Ann Intern Med. 2013;158:890-902.

  29. Tannoury CA, An HS. Complications with the use of bone morphogenetic protein 2 (BMP-2) in spine surgery. Spine J. 2014;14:552-9.

  30. Singh K, Nandyala SV, Marquez-Lara A, et al. Clinical sequelae after rhBMP-2 use in a minimally invasive transforaminal lumbar interbody fusion. Spine J. 2013;13:1118-25.

  31. Abstracts of the 22nd Annual Meeting of the North American Spine Society, October 23-27, 2007, Austin, Texas, USA. Spine J. 2007;7(5 Suppl):1S-163S.

  32. Lykissas MG, Aichmair A, Sama AA, et al. Nerve injury and recovery after lateral lumbar interbody fusion with and without bone morphogenetic protein- 2 augmentation: a cohort-controlled study. Spine J. 2014;14:217-24.




2020     |     www.medigraphic.com